Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies | Zendy

Francis de Zegher | Zendy; Nele Reynaert | Zendy; Lien De Somer | Zendy; Carine Wouters | Zendy; Mathieu Roelants | Zendy

Open Access

Growth Failure in Children with Systemic Juvenile Idiopathic Arthritis and Prolonged Inflammation despite Treatment with Biologicals: Late Normalization of Height by Combined Hormonal Therapies

Author(s) -

Francis de Zegher,

Nele Reynaert,

Lien De Somer,

Carine Wouters,

Mathieu Roelants

Publication year - 2018

Publication title -

hormone research in paediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.816

H-Index - 89

eISSN - 1663-2826

pISSN - 1663-2818

DOI - 10.1159/000489778

Subject(s) - medicine , triptorelin , glucocorticoid , short stature , endocrinology , hormone , growth hormone treatment , inflammation , growth hormone , gonadotropin releasing hormone , luteinizing hormone

Biologicals targeting the interleukin (IL)-1β or IL-6 pathway are becoming prime choices for the treatment of children with systemic juvenile idiopathic arthritis (sJIA). Up to 1 in 3 sJIA children receiving such treatment continues to have inflammatory activity and to require supra-physiological glucocorticoid doses which may reduce growth velocity for years and may lead to an extremely short stature for age, if not for life. Currently, there is no long-term proposal to normalize the adult height of these children with sJIA.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research